Drug Profile
Research programme: cancer therapy - CellGenix Technologie Transfer
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator CellGenix Technologie Transfer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Germany
- 10 Aug 2007 Preclinical trials in Cancer in Germany (unspecified route)